CSPG4 and cancer: As bone-marrow mesenchymal stem/progenitor cells are widely known to express NG2/CSPG4, an extension of the above conjecture would be that antibody blockade of the proteoglycan may exert a bivalent destabilization of both the cancer cells and their microenvironmental supportive cells.